Versant Venture Management LLC held its position in shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,048,601 shares of the biopharmaceutical company’s stock at the end of the second quarter. CymaBay Therapeutics accounts for approximately 1.8% of Versant Venture Management LLC’s investment portfolio, making the stock its 5th largest position. Versant Venture Management LLC’s holdings in CymaBay Therapeutics were worth $1,825,000 as of its most recent SEC filing.
Separately, Renaissance Technologies LLC raised its position in shares of CymaBay Therapeutics by 82.3% in the first quarter. Renaissance Technologies LLC now owns 111,000 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 50,100 shares in the last quarter. 30.37% of the stock is currently owned by institutional investors and hedge funds.
CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded down 0.58% on Friday, hitting $1.71. 9,078 shares of the stock were exchanged. The company’s 50 day moving average is $2.08 and its 200 day moving average is $2.00. The stock’s market cap is $40.09 million. CymaBay Therapeutics Inc. has a 1-year low of $0.82 and a 1-year high of $3.04.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.02. On average, equities research analysts expect that CymaBay Therapeutics Inc. will post ($1.20) earnings per share for the current year.
CBAY has been the subject of several recent analyst reports. Roth Capital initiated coverage on shares of CymaBay Therapeutics in a report on Friday, July 1st. They set a “buy” rating for the company. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 20th.
In other news, Director Robert James Wills acquired 25,000 shares of CymaBay Therapeutics stock in a transaction dated Tuesday, September 6th. The stock was acquired at an average cost of $2.43 per share, for a total transaction of $60,750.00. Following the completion of the purchase, the director now owns 25,000 shares of the company’s stock, valued at $60,750. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.00% of the stock is currently owned by insiders.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc. (NASDAQ:CBAY).
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.